Glaxo, SK Bioscience Hold Trials For New COVID Jab
British drugs giant GlaxoSmithKline and South Korean peer SK bioscience have begun final stage trials of a COVID-19 jab after positive early results, they announced Tuesday.The vaccine is facing a Phase 3 clinical trial to assess its "safety and immunogenicity" when compared with AstraZeneca's COVID vaccine, the two companies said in a joint statement.GSK is still trailing in the wake of Anglo-Swedish rival AstraZeneca, which rapidly developed a successful jab alongside Oxford